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Introduction: A recent meta-analysis suggested that patients 
with non–small-cell lung cancer (NSCLC) whose primary tumors 
have a higher standardized uptake value (SUV) derived from 
18F-fluorodeoxyglucose positron emission tomography (PET) have a 
worse prognosis in comparison with those with tumors with lower 
values. However, previous analyses have had methodological weak-
nesses. Furthermore, the prognostic significance over the full range 
of SUV values in patients treated nonsurgically remains unclear. The 
aim of this retrospective study was to investigate the relationship 
between survival and maximum SUV (SUV
max
) analyzed as a contin-
uous variable, in patients with NSCLC, staged using PET/computed 
tomography (CT) and treated with radiotherapy with or without 
chemotherapy.
Methods: Eligible patients had a histological diagnosis of NSCLC, 
were treated with radical radiotherapy with or without chemotherapy 
as their primary treatment, and had pretreatment PET/CT scans. 
SUV
max
, defined as the maximum pixel SUV value retrieved from the 
primary tumor, was analyzed primarily as a continuous variable for 
overall survival.
Results: Eighty-eight patients met eligibility criteria: stage I, 19; 
stage II, 10; and stage III, 59. Median SUV
max
 was 15.0 (range, 
2.5–56). Higher stage was associated with higher SUV
max
 values 
(p = 0.048). In univariate analysis, there was no evidence of a prog-
nostic effect of SUV
max
 (hazard ratio per doubling = 0.83; 95% 
confidence interval, 0.62–1.11; p = 0.22). Analyzing SUV
max
 as a 
dichotomous variable (median cut point = 15.0), the hazard ratio 
(high: low) for risk of death was 0.71, with p = 0.18 (95% confidence 
interval, 0.44–1.15).
Conclusions: In this cohort of patients, increasing SUV
max
 derived 
from 18F-fluorodeoxyglucose–PET/CT was associated with increas-
ing tumor, node, metastasis (TNM) stage. We found no evidence of 
an association of increasing SUV
max
 with a shorter survival. Previous 
reports of an association between prognosis and SUV
max
 may partly 
be the result of methodological differences between this study and 
previous reports and an association between stage and SUV
max
.
Key Words: Non–small-cell lung cancer, Positron emission tomog-
raphy, Standardized uptake value, Prognosis.
(J Thorac Oncol. 2014;9: 377–382)
In patients with non–small-cell lung cancer (NSCLC), the most important tumor-related prognostic factor is the 
tumor, node, metastasis (TNM) stage.1 The current nonin-
vasive standard for tumor staging is hybrid positron emis-
sion tomography/computed tomography (PET/CT) using 
18F-fluorodeoxyglucose (FDG). PET/CT has been shown to 
provide more precise anatomical and functional interpreta-
tions than PET or CT imaging alone.2
In addition to its efficacy in assessing nodal and meta-
static disease, FDG-PET/CT is thought to have a potential role 
as a prognostic factor. FDG uptake is commonly expressed 
as the standardized uptake value (SUV), a semiquantitative 
value defined as the tissue concentration of FDG in the region 
of interest divided by the injected dose normalized by body 
weight.
An update of the systematic review and meta-analysis 
of previous published studies, in which many patients were 
treated surgically and staged with FDG-PET,3,4 has sug-
gested that the maximum SUV (SUV
max
) of the primary 
tumor derived from 18F-FDG-PET scanning is potentially a 
prognostic indicator for outcome for patients with NSCLC. 
Nonetheless, this was not a consistent finding across all 
studies, which consisted mainly of patients with early-stage 
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disease (stage IIB or less). Furthermore, most studies exam-
ined the effect of SUV
max
 as a dichotomous variable, using 
a cutoff value equal in most case to either the median or a 
so-called best cut point determined from the data, which will 
therefore vary from one study population to another.
Given the superiority of hybrid FDG-PET/CT in provid-
ing more accurate staging, in this study we assessed the sur-
vival outcomes of medically or surgically inoperable NSCLC 
patients treated with radical radiotherapy (RT) or chemoirra-
diation at our institution. The aim was to determine whether 
primary tumor SUV
max
, derived from the initial pretreatment 
FDG-PET/CT and evaluated as a continuous variable, pro-
vides prognostic information for overall survival (OS) inde-
pendently of tumor stage.
Secondary objectives were to (1) assess the effect of 
SUV
max
 on progression-free survival (PFS), (2) examine for 
any correlations between SUV variables and baseline patient 
and tumor variables, and assess whether there are any inter-
actions between the above variables in their relationship to 
outcome. A further secondary objective was to examine the 
methodological validity of the “best cut point” method, using 
our data.
METHODS
Study Design
This was a retrospective cohort study of patients with 
NSCLC receiving radical RT at the Peter MacCallum Cancer 
Centre (Peter Mac) between January 2000 and December 2006.
Patient Selection
Before data collection, the study protocol was approved 
by the ethics committee of the Peter Mac. Eligible patients 
were identified via the Peter Mac PET Centre and RT data-
bases if they met the following criteria: histological diagnosis 
of NSCLC, received radical RT (60 Gy in 30 fractions) with or 
without concurrent chemotherapy as their primary treatment, 
were at least 18 years or older at commencement of treatment, 
and had pretherapeutic imaging with an integrated PET/CT 
scanner (GE Discovery LS PET/CT scanner, Milwaukee, WI). 
Hence, patients who had stand-alone PET imaging instead of 
PET/CT scanning before treatment were excluded from this 
study. Other exclusion criteria were a history of other malig-
nancies within the last 5 years (with the exception of in situ 
carcinoma and nonmelanoma skin cancer), prior treatment for 
NSCLC including surgery, and evidence of metastasis before 
treatment.
Data Collection
Patient demographics and potential prognostic factors 
were collected from the review of the hospital’s electronic 
medical records. This included tumor histology and differ-
entiation, NSCLC stage according to TNM classification of 
malignant tumors (6th edition), Eastern Cooperative Oncology 
Group (ECOG) performance status, weight loss over the 3 
months before diagnosis, smoking status, lung function, and 
Simplified Co-morbidity Score.5
RT treatment details and chemotherapy regimen, if 
applicable, and relevant parameters from PET/CT scanning 
details were recorded.
FDG-PET/CT Imaging Technique 
and Interpretation
An integrated PET/CT scanner (GE Discovery LS 
PET/CT scanner) was used for all patients in this study. 
Patients were required to fast 4 to 6 hours before PET/CT 
imaging. FDG-PET/CT scans encompassing the lower neck 
to the proximal thighs were performed on the combined 
PET/CT scanner. Image acquisition started at approximately 
1 hour after FDG injection. Contemporaneous noncontrast CT 
scans were performed for the purposes of attenuation correc-
tion and anatomical correlation.
SUV Methodology
SUV
max
 was derived using an SUV threshold isocontour 
based volume of interest around the primary tumor. The operator 
defined a volume manually around the entire tumor but exclud-
ing nearby benign structures with FDG avidity. The operator had 
discretion for selecting the SUV contour for the tumor, but usu-
ally a value of 4. In-house software (MARVN 2.16) was used 
to manually draw the region of interest placed over the entire 
primary lung tumor and to calculate SUV. An ellipsoid volume 
of interest was placed over a representative region of the liver 
from which the patient’s mean liver SUV was recorded. This was 
used as a quality assurance parameter to ensure concordance of 
SUV
max
 measurements. The percentage of FDG uptake by the 
primary lung tumor (% dose) was also recorded.
Endpoint Definitions
Time-to-event endpoints
Patients were followed to the end of 2008, and dates of 
disease progression and death recorded. After 2008, follow-up 
was incomplete and so a close out date was used to minimize 
reporting bias.
The start date for all time-to-event outcomes was the 
date of commencement of RT. OS was defined as time to death 
from any cause. PFS was defined as time to progression or 
death. All times were censored at the end of 2008 and by the 
date of last follow-up in patients lost to follow-up.
Statistical Analysis
The primary aim was to assess whether SUV
max
 was 
related to OS after adjusting for T stage. Secondary aims were 
to assess the relationship between SUV
max
 and PFS.
Baseline patient and tumor characteristic distributions 
were tabulated and their association with SUV
max
 examined 
using Wilcoxon or Kruskal-Wallis tests for categorical vari-
ables and Spearman rank correlation coefficients for continu-
ous variables. SUV
max
, SUV
mean
, and percentage dose were 
transformed to normalize their distribution using logarithms 
to base 2; this allows the interpretation of hazard ratios (HRs) 
in terms of doublings.
Survival curves were calculated using the Kaplan–Meier 
method and compared using the log-rank test. The median 
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potential follow-up time for the study was calculated using 
the reverse Kaplan–Meier method.6
The assessment of the relationship of baseline variables 
to OS and PFS was undertaken using Cox regression for con-
tinuous variables or when assessing multiple variables simul-
taneously. The log-rank test was used to assess the relationship 
of single categorical variables to outcome. A Cox regression 
model with an interaction term was used to assess whether 
the prognostic effect of SUV
max
 differed according to the level 
of another factor (T stage, ECOG performance status, and 
histology). The relationship of SUV
max
 to the relative hazard 
rate (mortality rate) as a continuous function was estimated 
graphically using a cubic spline fitted to martingale residuals 
from a Cox model.
The best cut point method in the context of these data 
determines the cutoff value for dichotomizing SUV
max
 as that 
value for which the p value comparing high and low SUV
max
 
groups with respect to OS is a minimum. We examined all 
possible cut point values between the 10th and 90th percen-
tiles of SUV
max
 to allow sufficient numbers of events in each 
group. We used two methods to obtain an adjusted p value 
to correct for the method by which the nominal p value was 
obtained: a formula given by Altman et al.6 and a permutation 
test. The Altman formula in our case is given by:
p p pcorr ≈ − +( )1 63 1 2 351. . log( )min min
where p
min
 is the minimum p value obtained (the nominal 
p value) and p
corr
 is the true (adjusted) p value. All analyses 
were undertaken using the R Statistical Package.
RESULTS
There were 88 patients who met eligibility criteria for 
analysis. Table 1 summarizes baseline characteristics and 
their relationship to SUV
max
 for the 88 PET/CT patients. The 
range of SUV
max
 was from 2.5 to 56; median = 15.0. Higher 
T stage was correlated with higher SUV
max
 (p = 0.048). There 
was a trend of higher nodal status and clinical stage to higher 
SUV
max
 (p = 0.52 and p = 0.3, respectively). Median SUV
max
 
values were 10.7 (T1), 14.0 (T2), 15.6 (T3), and 16.0 (T4). 
Squamous cell carcinoma histology was associated with 
higher values of SUV
max
 (p = 0.002): median values of SUV
max
 
were squamous cell carcinoma 16.4, adenocarcinoma 11.1, 
and other histologies 12.6.
Analyses of Outcomes
Of the 88 patients, there were 69 deaths (53 
 cancer-related), and 58 patients had documented disease 
progression (30 locoregionally and 45 in metastatic sites). 
Seventy-two patients had either progressive disease or died 
(or both). Only one patient was lost to follow-up (after 3 
months). The median potential follow-up time was 53 months 
and ranged from 26 to 81 months in the 87 patients not lost 
to follow-up.
There was no statistically significant relationship between 
log (SUV
max
) and OS (p = 0.21; HR = 0.83; Table 2). A simi-
lar result was obtained when assessing SUV
max
 adjusting for T 
stage (p = 0.12; HR [per doubling of SUV
max
] = 0.78; Table 2). 
Figure 2 shows the risk of death as a continuous function across 
the range of SUV
max
 values observed, with no indication of 
worsening outcome (in fact observed risk of dying decreases).
When comparing high and low SUV
max
 dichotomized at 
the median (15.0), HR (high: low) = 0.72; 95% confidence 
interval = 0.44 to 1.14; p = 0.18 (Fig. 1A). A HR of 1.14 repre-
sents less than 5% difference in OS rates at the overall median 
survival time, indicating that there is no prognostic effect of 
increasing SUV
max
 resulting in an adverse outcome. SUV
max
 
grouped using quartile cut points (10.5, 15.0, 19.0) indicated 
relative hazard rates of 1.15, 1.21, 0.87, and 0.82 for increas-
ing SUV
max
 groups, respectively (p
trend
 = 0.21; Fig. 1B).
Tests for interaction indicated no evidence for a prog-
nostic effect of SUV
max
 differing by subgroup of T stage 
(p = 0.79), ECOG performance status (p = 0.66), or histol-
ogy (p = 0.39). Analyses of other continuous SUV variables 
(mean, percentage dose uptake in tumor) on OS and PFS pro-
duced very similar results (Table 2).
Best Cut Point Method
The data were analyzed according to the “best cut point 
method” for the analysis of OS by SUV
max
. Figure 3 shows 
the nominal p value and HR at each examined cut point plot-
ted against the cut point value. The smallest p value (0.020) 
occurred at 12.6 (39th percentile of SUV
max
), corresponding 
to a HR of 0.58. Using the formula given by Altman et al.6 to 
obtain a corrected p value gave p
Altman
 = 0.28. The alternative 
permutation test method gave p
perm.
 = 0.23 (SE = 0.004).
DISCUSSION
This study has demonstrated that in patients treated with 
radical RT for inoperable NSCLC, higher SUV
max
 derived from 
a staging FDG-PET/CT scan does not significantly correlate 
with poorer survival. Our data did demonstrate that increasing 
SUV
max
 was associated with increasing stage and squamous 
histology. After adjusting for these factors, there was still no 
clear and consistent adverse prognostic effect of higher SUV.
To our knowledge, this is the only published study 
investigating the prognostic potential of SUV
max
 using inte-
grated PET/CT (rather than PET only) before commencing 
treatment in a cohort of patients with NSCLC treated non-
surgically, either with radical RT or chemoradiation. Due to 
technical factors, including superior attenuation correction, 
PET/CT provides a more accurate value for SUV than stand-
alone PET.7 The aim of this study was to assess whether 
SUV
max
 had independent prognostic value after adjusting for 
tumor stage in this group of patients. We analyzed the effect 
of SUV
max
 as both a dichotomous and a continuous variable 
because if an effect exists it cannot be assumed that the effect 
is consistent across the full range of values.
This study therefore does not support the result of the 
meta-analysis.4 There are several reasons that could contribute 
to these findings.
FDG uptake is a surrogate for increased glucose metab-
olism, which has been thought to represent tumor cell activ-
ity.8,9 However, the exact mechanism of FDG activity and 
distribution within malignant tumors is not fully understood. 
FDG is not only taken up in malignant tumor cells but may 
reflect other metabolic processes within the heterogeneous 
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cellular components of the tumor, such as tumor hypoxia, 
inflammation, or necrosis, which are unrelated to tumor 
aggressiveness.10
Furthermore, the conclusions drawn from the results of 
the meta-analysis should be treated with caution, as the patient 
groups included in the studies included in the meta-analysis 
were highly selected both by stage and by treatment. Studies 
in patients with more advanced disease or those treated by 
nonsurgical means alone were underrepresented. The small 
proportion of patients with locoregionally advanced disease 
could have influenced the results. For example, in the study by 
Hoang et al.11 of patients with more advanced disease (some 
treated with RT), FDG SUV
max
 was found not to have a signifi-
cant relationship with survival.
There has been a recent study investigating the role 
of SUV values obtained following therapy in patients with 
NSCLC treated with chemoradiation,12 and initial findings are 
suggestive of an association between higher post-treatment 
SUV values and worse survival. Interestingly, as part of their 
exploratory analysis of pretreatment SUV values, no associa-
tion with survival was found.
Although there have been previous studies4,13 with 
patients managed surgically that have shown reduced OS and 
disease-free survival in patients with higher SUV
max
 values, 
TABLE 1.  Clinicopathological Characteristics of Study Cohort
Variable Level n %
SUV
max
pMedian (range)
Sex Male 58 66 15.4 (2.5–56.1) 0.33
Female 30 34 12.4 (2.9–45.6)
Age ≤70 44 50 14.2 (2.5–56.1) 0.14
>70 44 50 15.5 (2.9–45.6)
ECOG PSa 0 21 25 14.8 (2.5–33.4) 0.98b
1 52 62 15.7 (2.9–56.1)
2 11 13 14.4 (5.4–21)
SCS ≤8 35 40 14.8 (6.8–45.6) 0.56
>8 53 60 15.1 (2.5–56.1)
Weight loss None 46 53 15.0 (2.5–45.6) 0.44b
<10% 30 35 15.1 (5.4–23.9)
>10% 10 12 12.2 (2.9–56.1)
T stage 1 9 10 10.7 (2.5–45.6) 0.054b
2 43 49 14.0 (2.9–33.8)
3 15 17 15.6 (9.8–36.3)
4 21 24 16.0 (7.3–56.1)
N stage 0 27 31 14.2 (2.5–45.6) 0.52b
1 12 14 16.5 (9.7–33.8)
2 43 49 14.6 (4.2–56.1)
3 6 7 15.7 (10.7–19.7)
Clinical stage 1 19 22 14.2 (2.5–45.6) 0.3b
2 10 11 14.8 (9.7–36.3)
3 59 67 15.1 (4.2–56.1)
Histology Adenocarcinoma 25 28 11.1 (2.5–45.6) 0.002c
SCC 44 50 16.4 (5.4–51.7)
Other 19 22 12.6 (6.7–56.1)
Differentiation Well 4 6 12.9 (4.2–25.9) 0.74b
Moderate 12 18 15.1 (2.9–33.8)
Poor, undifferentiated 49 75 14.6 (5.4–56.1)
Chemotherapy No 20 23 12.0 (2.5–36.3) 0.073
Yes 67 77 15.3 (2.9–56.1)
Smoking ≤40 45 52 14.4 (2.5–51.7) 0.86
>40 42 48 15.1 (5.4–56.1)
p values (p) test for association between the variable and SUV
max
.
aECOG PS.
bp value for trend.
cp value for any group differences.
SUV
max
, standardized uptake value maximum; ECOG PS, Eastern Cooperative Oncology Group performance status; SCS, Simplified Co-morbidity Score; SCC, squamous cell 
carcinoma.
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these values were derived from pretreatment stand-alone PET 
scans (as opposed to PET/CT) scans. More recently, Cistaro 
et al.14 reported worse 2-year outcomes with presurgical SUV
max
 
values above the calculated best cutoff value using PET/CT 
scanners. These studies had small sample sizes, and most were 
limited to patients with early-stage, resectable disease.
Some published reports suggest that there is a poten-
tial difference between absolute SUVs measured using 
PET and PET/CT.15,16 To ensure homogeneity in our study 
cohort, patients who had surgical management as part of 
their therapy or were staged with PET only were excluded 
from the study.
TABLE 2.  Univariable and Multivariable Cox Regression Analyses of the Relationship of SUV as a Continuous Variable on OS 
and PFS
Outcome Factor HR CI p
OS log
2
(SUV
max
) 0.83 0.62–1.11 0.21
OS (multivariable analysis) log
2
(SUV
max
) 0.78 0.57–1.06 0.12
T stage 0.15 0.93–1.58 0.15
PFS log
2
(SUV
max
) 0.88 0.67–1.16 0.36
PFS (multivariable analysis) log
2
(SUV
max
) 0.83 0.62–1.11 0.22
T stage 1.19 0.92–1.53 0.18
Of the 88 patients, 69 had died and 72 had progressed or died (or both). Multivariable analyses assess log
2
(SUV
max
) adjusting for T stage.
SUV
max
, standardized uptake value maximum; OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval.
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Our primary analysis used SUV
max
 as a continuous vari-
able. This is generally to be preferred to dichotomizing the 
variable as it is more powerful (information is not discarded) 
and is not subject to the arbitrariness of choice of cut point. 
This latter point is demonstrated in the example provided from 
our own data, where a cut point of SUV
max
 = 12.6 divided 
patients into groups, which were (nominally) statistically sig-
nificantly different, but the median SUV
max
 of 15.0 was not.
In many previous publications that report a poor out-
come with higher SUV values, the prognostic value of SUV 
was assessed by dichotomizing patients according to the “best 
cut point” method. As this method involves multiple tests 
based on a large number of potential cut points and choos-
ing the one with smallest p value, the approach is associated 
with a large type I error rate—an inbuilt tendency to produce 
significance where no difference exists. A correction has to be 
made to the p value to make this a valid analysis, a practice 
that is commonly ignored. The analysis of our data using the 
best cut point method gave a “significant” nominal p value 
of 0.020, which after correction was reduced to a modest 
p = 0.23, consistent with the continuous variable analysis. The 
type I error rate using the uncorrected best cut point method in 
a study of the size of ours can be approximately 40%.
We acknowledge that there are limitations in our study, 
including the fact that this is a single institution retrospec-
tive study with relatively small numbers. It has been hypoth-
esized that the impact of SUV
max
 on prognosis may be stage 
dependent—that in patients with more advanced stages, the 
metabolic activity measured by SUV
max
 on the primary tumor 
has lower prognostic value as it has been subsumed by the 
anatomic extent of the tumor.4 We did not observe evidence 
for such a dependency in our data for T stage (or for ECOG 
performance status or histology).
Alternatively, it is possible that the relationship between 
primary tumor FDG uptake and survival, if present, could be a 
biphasic rather than linear relationship, with a limited role on 
prognosis in more advanced stage disease. It is clear from our 
data that further prospective, methodologically sound studies 
with larger sample sizes are required before it is possible to 
draw sound conclusions about the prognostic significance of 
SUV
max
 in NSCLC.
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